Zacks Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Zacks Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,729	Closed	-$1.23M	–	742
2025 Q3	$1.23M	Sell	22,729 -31	-0.1%	-$1.77K	0.01%	392
2025 Q2	$1.25M	Sell	22,760 -698	-3%	-$41.1K	0.01%	378
2025 Q1	$1.66M	Buy	23,458 +3,259	+16%	+$219K	0.02%	350
2024 Q4	$1.33M	Buy	20,199 +2,397	+13%	+$161K	0.01%	381
2024 Q3	$1.25M	Sell	17,802 -3,771	-17%	-$315K	0.01%	389
2024 Q2	$1.78M	Buy	21,573 +1,611	+8%	+$134K	0.02%	306
2024 Q1	$1.74M	Buy	+19,962	New	+$1.79M	0.02%	333
2019 Q1	–	Sell	-15,183	Closed	-$1.29M	–	538
2018 Q4	$1.29M	Buy	+15,183	New	+$1.44M	0.03%	302
2016 Q1	–	Sell	-4,188	Closed	-$439K	–	608
2015 Q4	$439K	Sell	4,188 -968	-19%	-$101K	0.01%	439
2015 Q3	$543K	Sell	5,156 -19	-0.4%	-$2.54K	0.02%	413
2015 Q2	$708K	Buy	+5,175	New	+$641K	0.02%	369
2014 Q4	–	Sell	-10,677	Closed	-$770K	–	635
2014 Q3	$770K	Buy	10,677 +274	+3%	+$18K	0.03%	307
2014 Q2	$647K	Buy	+10,403	New	+$628K	0.02%	362

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Zacks Investment Management's BMRN Position: Q4 2025 in Review

Zacks Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 22,729 shares — an estimated $1.23M sold.

Zacks Investment Management first reported a position in BMRN in Q2 2014 and held it in 13 quarters. The position peaked at $1.78M in Q2 2024. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Zacks Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Zacks Investment Management sold 22,729 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.23M.
Zacks Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 13 quarters.
Zacks Investment Management's BioMarin Pharmaceuticals position peaked at $1.78M in Q2 2024.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Zacks Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.